N-Terminal Pro-B-type Natriuretic Peptide Levels in the Korean General Population.
OBJECTIVE
B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) levels may serve as a useful marker of cardiovascular risk for screening of the general population. We evaluated reference levels and distribution of NT-proBNP in the Korean general population based on a large cohort study.


METHODS
We included 1,518 adult subjects (ages 40-69) of a community-based cohort from the Korea Rural Genomic Cohort (KRGC) Study. Thorough biochemical and clinical data were recorded for all subjects. Levels of NT-proBNP from all participants were determined. In order to determine normal reference levels, subjects with factors known to influence NT-proBNP levels were excluded.


RESULTS
The characteristics of the cohort are described below; subjects were 41.2% male, and the mean age was 54.8±8.4 years. The distribution of risk factors for cardiovascular disease in the cohort included hypertension (25%), left ventricular hypertrophy by electrocardiography (ECG-LVH) (15%), hypercholestolemia (4.5%), smoking (32%), diabetes (10.9%), history of coronary heart disease (4.9%), history of heart failure (0.9%), symptoms of heart failure (6.1%), elevated serum creatinine (≥1.5, 3.7%), and severe obesity (body mass index >30 kg/m(2), 4.6%). The levels of NT-proBNP of all subjects are shown below; the mean was 60.1±42.1, and the median was 36.5 pg/mL. In addition, the levels of NT-proBNP of normal subjects (which did not have any risk factors, n=224) are shown below; the mean was 40.8, and the median was 32.1 pg/mL. In normal subjects, the NT-proBNP level was slightly higher in females (25.7±24.8 vs. 46.9±35.4, p<0.001). NT-proBNP level increased with age in both the normal population and the total population. There were no significant differences in NT-proBNP levels in subjects who smoked, or had diabetes mellitus, hypertension or ECG-LVH. However, in subjects with a history of congestive heart failure (CHF) (58.5±103.29 vs. 213.8±258.8, p<0.005), elevated serum creatinine levels (≥1.5 mg/dL, 146.2±98.2 vs. 54.3±38.1, p<0.001), or who were older (≥60, 48.4 vs. 84.2±139.5 pg/mL, p<0.05), the BNP level was higher. In addition, patients with more than 3 risk factors for CHF had higher BNP levels (risk 0: 40.8±34.0, 1-2: 57.4±93.2, ≥3: 85.0±152.9 pg/mL). NT-proBNP levels were also related with age, sex, urine albumin, serum Cr, and high sensitivity C-reactive protein (p<0.05).


CONCLUSIONS
We determined the reference value and distribution of NT-proBNP in the Korean adult general population. We also found that adjustments for the independent effects of age, sex and renal function appear necessary when determining cardiac risk based on proBNP levels.
Division of Cardiology, Gachon University of Medicine and Science, Gil Medical Center, Incheon, Korea.
Kyung-Hoon
KH
Lee
Jang-Young
JY
Kim
Sang-Baek
SB
Koh
Seung-Hwan
SH
Lee
Junghan
J
Yoon
Sang-Woo
SW
Han
Jong-Ku
JK
Park
Kyung-Hoon
KH
Choe
Byung-Su
BS
Yoo
Am J Cardiol. 2008 Feb 4;101(3A):29-38
18243855
J Am Coll Cardiol. 2002 Sep 4;40(5):976-82
12225726
Clin Chem. 2006 Dec;52(12):2229-35
17053156
Eur Heart J. 2005 Nov;26(21):2269-76
16040618
J Am Coll Cardiol. 2000 Apr;35(5):1256-62
10758968
J Card Fail. 2006 Aug;12(6):452-7
16911912
Diabetes Care. 2004 Aug;27(8):1929-35
15277419
Circulation. 2003 Jul 8;108(1):13-6
12821537
N Engl J Med. 2008 Aug 14;359(7):760-1; author reply 761
18711791
Am J Med. 1992 Jan;92(1):29-34
1530996
Clin Chem Lab Med. 2004;42(8):942-4
15387447
Am J Cardiol. 2008 Feb 4;101(3A):21-4
18243853
Eur Heart J. 2006 Dec;27(24):3004-10
17118955
J Pharmacol Exp Ther. 1999 May;289(2):976-80
10215677
Lancet. 1997 Nov 8;350(9088):1349-53
9365448
Intern Med J. 2008 Feb;38(2):101-13
18290826
Heart. 2002 Feb;87(2):131-5
11796549
Int Heart J. 2005 May;46(3):465-75
16043942
N Engl J Med. 2004 Feb 12;350(7):655-63
14960742
Heart. 2003 Jul;89(7):745-51
12807847
Congest Heart Fail. 2008 Jul-Aug;14(4 Suppl 1):5-8
18772638
Circulation. 1997 Jul 15;96(2):509-16
9244219
N Engl J Med. 2002 Jul 18;347(3):161-7
12124404
Circulation. 2004 Feb 10;109(5):594-600
14769680
Clin Chem. 2007 Jun;53(6):1075-83
17446333
Am J Cardiol. 2008 Aug 15;102(4):469-74
18678308
J Am Coll Cardiol. 2001 Feb;37(2):379-85
11216950
J Am Coll Cardiol. 2003 Jun 18;41(12):2280-7
12821260
Am J Cardiol. 2008 Feb 4;101(3A):9-15
18243867